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Abstract
Background: We identified two 3p21.3 regions (LUCA and AP20) as most frequently affected in lung, breast and other
carcinomas and reported their fine physical and gene maps. It is becoming increasingly clear that each of these two regions
contains several TSGs. Until now TSGs which were isolated from AP20 and LUCA regions (e.g.G21/NPRL2, RASSF1A, RASSF1C,
SEMA3B, SEMA3F, RBSP3) were shown to inhibit tumour cell growth both in vitro and in vivo.
Methodology/Principal Findings: The effect of expression HYAL1 and HYAL2 was studied by colony formation inhibition,
growth curve and cell proliferation tests in vitro and tumour growth assay in vivo. Very modest growth inhibition was
detected in vitro in U2020 lung and KRC/Y renal carcinoma cell lines. In the in vivo experiment stably transfected KRC/Y cells
expressing HYAL1 or HYAL2 were inoculated into SCID mice (10 and 12 mice respectively). Tumours grew in eight mice
inoculated with HYAL1. Ectopic HYAL1 was deleted in all of them. HYAL2 was inoculated into 12 mice and only four tumours
were obtained. In 3 of them the gene was deleted. In one tumour it was present but not expressed. As expected for tumour
suppressor genes HYAL1 and HYAL2 were down-expressed in 15 fresh lung squamous cell carcinomas (100%) and clear cell
RCC tumours (60–67%).
Conclusions/Significance: The results suggest that the expression of either gene has led to inhibition of tumour growth in
vivo without noticeable effect on growth in vitro. HYAL1 and HYAL2 thus differ in this aspect from other tumour suppressors
like P53 or RASSF1A that inhibit growth both in vitro and in vivo. Targeting the microenvironment of cancer cells is one of
the most promising venues of cancer therapeutics. As major hyaluronidases in human cells, HYAL1 and HYAL2 may control
intercellular interactions and microenvironment of tumour cells providing excellent targets for cancer treatment.
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Introduction
We have performed a deletion survey of 3p on more than 400
lung, renal, breast, cervical and ovarian carcinomas using a
defined set of markers, combining conventional LOH (loss of
heterozygosity) with quantitative real-time PCR (qPCR), compar-
ative genomic and NotI microarrays hybridisations [1–5]. We
identified two most frequently affected 3p21.3 regions, LUCA at
the centromeric and AP20 at the telomeric border of 3p21.3.
Aberrations of either region were detected in more than 90% of
the studied tumours. Homozygous deletions (HD) were detected in
10%–18% of all tumours at both the LUCA and AP20 sites [4,5].
The frequent chromosome losses in these regions suggest that they
harbor multiple tumour suppressor genes (TSG) [6–8]. It was
suggested that aberrations in both the LUCA and AP20 region
could be functionally linked [5,9,10].
The definition of a TSG is based on the demonstration of its
regular inactivation by mutation or epigenetic silencing in tumour
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samples. It is also important to obtain supportive evidence from
functional studies. We have previously found (in collaboration with
Stefan Imreh et al.) non-random losses of human 3p21-p22
fragments from mouse-human microcell hybrids following pro-
gressive growth in SCID mice [11]. In order to test whether a
known suppressor gene, RB, would behave in a similar way, wild
type and mutated RB genes were introduced into the pETE
(Elimination Test Episomal) vector that permitted the expression
of the gene in the absence but not in the presence of tetracycline.
The expression of the gene could be modulated by tetracycline
both in vivo and in vitro. When the transfectants were passaged as
tumours in immunodeficient SCID mice, the wild type RB gene
was deleted or functionally inactivated already after the first
passage in all 20 tumours tested. In contrast, a non-functional
mutant RB gene was maintained in all 10 tumours studied. In
similar experiments with wt P53, the exogenous P53 gene was
maintained and expressed in all 6 tumours tested, but in a mutated
form. On the basis of these experiments we have developed the
gene inactivation test (GIT) for a functional definition of TSG. It is
based on the comparison of cell growth in vitro and tumour growth
in vivo when the gene is/is not expressed. The main idea of the test
is that a gene inhibiting growth of tumour cells should be
inactivated in growing tumours by genetic or epigenetic
mechanisms.
Using GIT and growth analysis under cultural conditions we
have shown that FUS1, SEMA3B, G21/NPRL2, RASSF1A,
RASSF1C, RBSP3 (genes from AP20 and LUCA regions) and
other TSGs inhibit tumour cell growth both in vitro and in vivo
[7,9,11–15].
However other genes from 3p21.3 (e.g. TCEA1, MLH1, RHOA,
3PK, PL6, 101F6, BLU, TGFBR2) did not show any effect in the
tested cell lines [11].
Here we describe the functional analysis of two additional genes
from the 3p21.3 LUCA region, hyaluronidases -1 and -2 (HYAL1
and HYAL2).
The HYAL1 gene (hyaluronoglucosaminidase 1) is located in the
LUCA region. It contains 6 exons producing a 2.6 kb mRNA
(coding for 436 aa protein). It is well expressed in all analysed
normal human tissues including lung and kidney. It was not
expressed in 18 out of 20 lung cancer cell lines [6].
The HYAL2 (hyaluronoglucosaminidase 2, located in LUCA
region) contains 4 exons producing a 2 kb mRNA (that encode
473 aa). It is well expressed in all analysed human tissues including
lung, kidney and many lung cancer cell lines. The protein is
attached to the membrane by the glycosylphosphatidyl-inositol-
anchor (GPI-anchor) [16]. The HYAL2 protein was identified as a
receptor for the sheep lung cancer retrovirus, JSRV, and a
sequestration mechanism inactivating HYAL2 protein was dem-
onstrated. The env gene of JSRV was shown to transform human
bronchial epithelial cells in vitro and sequesters the HYAL2 protein.
The absence of HYAL2 (mediated either by a putative virus or
mutational inactivation) leads to ligand-independent activation of
the RON receptor tyrosine kinase and its downstream AKT and
MAPK signaling pathways [17].
These two genes contribute to intracellular and extracellular
catabolism of hyaluronic acid (HA) in a CD44-dependent manner
[18]. HA has a great number of biological functions: it mediates
cell-cell and cell-matrix interactions and plays an important role in
cell migration, tumour growth and progression.
Thus analysis of HYAL1 and HYAL2 can have a great
importance not only for better understanding of HA catabolism
and human carcinogenesis but could provide therapeutic targets
for cancer treatment. In this study we have found that the
expression of either gene suppressed tumour growth in vivo but not
in vitro. These findings are consistent with earlier somatic hybrid
studies by Henry Harris, George Klein and Francis Wiener,
showing that somatic hybridisation of normal and malignant cells
can suppress tumorigenicity in vivo but not cell growth in vitro
[19,20]. The mechanisms of the in vivo suppressive effects have not
been clarified, but at least part of them may have acted at the level
of tumour-host interactions. The finding of a similar phenomenon
with the two genes involved in the present study is a step towards
the analysis of this important phenomenon.
Results
Colony formation inhibition by HYAL1 and HYAL2 in vitro
In this study we performed initial functional analysis of HYAL1
and HYAL2. These genes are located in the minimally deleted
region of LUCA (Figure 1). The work was a continuation of our
previous study to characterize different genes, located in the same
region, e.g. RASSF1A [13], RASSF1C [14] and G21/NPRL2 [15].
These studies showed that these genes have strong growth
inhibiting activity both in vitro and in vivo.
Expression of HYAL1 and HYAL2 was almost undetectable in
the KRC/Y renal and U2020 lung carcinoma lines (data not
shown), which were used in our growth suppression experiments
for testing RASSF1A and G21/NPRL2 [13–15]. As both HYAL1
and HYAL2 are well expressed in normal kidney and lung (see for
example http://www.genecards.org/index.shtml) we have chosen
KRC/Y and U2020 for our study.
HYAL1 and HYAL2 were cloned into the episomal tetracycline-
regulated pETE-Hyg vector [21] and used for transfection of the
KRC/Y and U2020 cells (for colony formation experiments,
Figure 2). The empty pETE vector was used as a negative control.
HYAL1 and HYAL2 showed almost no inhibition of colony
formation. When HYAL1 and HYAL2 were expressed the cloning
efficiency was 77–100%, compared to the empty vector. As a
positive control we used FUS1 gene, a strong TSG cloned in pETE
[7]. Colony formation efficiency of the KRC/Y cells expressing
FUS1 was less than 5% and for U2020 cells it was less than 25%
compared to controls.
Figure 1. Schematic map of the LUCA region picturing the
HYAL1 and HYAL2 genes.
doi:10.1371/journal.pone.0003031.g001
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We performed also growth curve inhibition experiments using
KRC/Y cells stably transformed with HYAL1 and HYAL2
transgenes. The pETE-HYAL1 and pETE-HYAL2 vectors
carrying wild type alleles of the tested genes were transfected into
KRC/Y expressing tTA and clonal cell lines were selected.
Expression of the transgenes was tested by Northern hybridization.
Two of the best tetracycline regulated clones for each gene were
then used in further experiments (see for example Figure 3A). For
HYAL1 clones 1 and 4 were selected (HYAL1-KRC/Ycl.1 and
HYAL1-KRC/Ycl.4) and for HYAL2 clones 13 and 14 (HYAL2-
KRC/Ycl.13 and HYAL2-KRC/Ycl.14). Growth curves for
HYAL1-KRC/Ycl.4 and HYAL2-KRC/Ycl.13 are shown in
Figure 3B and C. Only modest growth inhibition was seen like in
the colony assays. Two other clones showed similar results.
In the same way we selected U2020 cell clones expressing
HYAL1 (HYAL1-U2020cl.4 and HYAL1-U2020cl.5) and HYAL2
(HYAL2-U2020cl.15 and HYAL2-U2020cl.18). All eight clones
expressing either HYAL1 or HYAL2 in KRC/Y and U2020 cells
were tested with CyQUANT NF Cell Proliferation Assay based on
measurement of cellular DNA content via fluorescent dye binding
(see Materials and Methods). Figure 4 shows that neither HYAL1
nor HYAL2 inhibited KRC/Y or U2020 cells to a significant
extent.
Gene inactivation test with HYAL1 and HYAL2 in SCID
mice
We investigated HYAL1 and HYAL2 using the gene inactivation
test (GIT) as described by Li et al., 1999 [22] and Protopopov et al.,
2002 [21]. The test mimics the inactivation of TSGs during
tumour growth in vivo. Clonal cell lines expressing transgenes were
inoculated into SCID mice and the expression of the transgene
was controlled by tetracycline administered ad libitum in the
drinking water. In this setting TSGs suppressed tumour formation
in SCID mice, unless they were eliminated or mutated. All grown
tumours were analysed for the presence and expression of the
transgene.
KRC/Y derived HYAL1 and HYAL2 cell clones were inoculated
into 22 SCID mice (6 mice/HYAL1-KRC/Ycl.1; 4 mice/
HYAL1-KRC/Ycl.4; 8 mice/HYAL2-KRC/Ycl.13 and 4 mice/
HYAL2-KRC/Ycl.14). For each SCID mouse, 56106 cells were
inoculated (one inoculation per mouse). In control mice, KRC/Y
cells transfected with empty pETE vector were used (twelve SCID
mice were injected). Half of the SCID mice were then given
drinking water containing 1mg/ml tetracycline. Results of these
experiments are shown in Figure 3D (to make Figure more clear
only curves for mice drinking water without tetracycline are
shown). In many cases no tumour growth was observed at all (see
Table 1). Strong inhibition of tumour growth was observed for all
clones expressing HYAL1 or HYAL2. All grown 12 tumours (T1–
T12) were explanted and tested for the presence of pETE-HYAL1
and pETE-HYAL2 constructs by PCR. Transgenes were detected
only in one tumour (HYAL2) and in eleven tumours it was deleted.
In tumour T10 where the HYAL2 gene was present by PCR, there
was no detectable expression by Northern (data not shown).
Expression of HYAL1 and HYAL2 genes is significantly
decreased in lung and kidney cancer samples
As our data suggested that both HYAL1 and HYAL2 induce
growth inhibition of tumours in SCID mice we tested expression of
these genes in lung and renal tumours using qPCR (see Materials
and Methods).
Fifteen SCC and fifteen RCC tumours were studied. We
assumed that expression fell down if it was at least 2-fold lower
than in matched control samples. Expression of both genes was
drastically decreased in all lung samples (15/15, P,0.02, Figure 5).
Average decrease level for HYAL1 was 7.8 (from 2.5 up to 77) and
for HYAL2 8.8 (2.5–53) times . In seven cases expression of HYAL1
fell down more than 10-fold. For HYAL2 eight such cases were
found. In six of fifteen lung biopsies we found more than 10-fold
decrease of both HYAL1 and HYAL2 expression. In RCC samples
expression of HYAL1 declined in 10 of 15 cases (67%, P,0.02) and
average decrease was 6.5 times (from 2 to 46). For HYAL2 reduced
Figure 2. Effect of HYAL1 and HYAL2 transgenes on colony formation efficiency in KRC/Y and U2020 cells compared to empty pETE
vector (negative control) and wild type or mutated FUS1 transgenes. Graphical representation summarizing three independent experiments
and photographic images of Petri dishes stained with methylene blue. Values are the mean6s.d. of three separate experiments each calculated from
triplicate plates.
doi:10.1371/journal.pone.0003031.g002
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expression was detected in 9 of 15 samples (60%, P,0.02) and
average decrease was 4.9 times (2–11.4). Only in three RCC
samples expression of HYAL1 decreased more than 10-fold and in
one case we detected similar strong decline of HYAL2 expression.
No statistically significant difference in cases with different tumour
stages was observed both in SCC and RCC cases.
Discussion
In this work we describe functional characterization of HYAL1
and HYAL2 genes. Using the GIT test we previously tested
altogether 15 genes from 3p21.3 LUCA and AP20 regions. Nine
genes (TCEA1, MLH1, VILL, RHOA, 3PK, PL6, 101F6, BLU,
TGFBR2) did not show any effect in the tested cell lines. Six genes
(RBSP3, NPRL2/G21, RASSF1A, RASSF1C, SEMA3B, SEMA3F)
had strong growth inhibitory activity, both in vitro and in vivo.
For example, NPRL2/G21 demonstrated growth inhibition in
vitro in small cell lung cancer cell line U2020 and renal carcinoma
cell line KRC/Y cells almost 90%. RASSF1A gene showed the
same results. In SCID mice both genes either did not permit
tumour formation or in growing tumours they were inactivated
(for NPRL2 it was 10 mice and for RASSF1A it was 8 mice).
In contrast, neitherHYAL1 norHYAL2 showed significant growth
inhibition in colony formation and growth curve assays in vitro (see
Figures 2–3). CyQUANT NF Cell Proliferation Assay (Figure 4)
also demonstrated that neither HYAL1 nor HYAL2 inhibited KRC/
Y or U2020 cells proliferation. Importantly, pETE vectors
expressed mRNA of inserted genes in quantity comparable to
physiologically normal levels [14]. However in SCID mice both
genes had a very strong inhibiting effect: no tumours grew in 10
mice and in 12 mice where tumours grew the genes were inactivated
(deletion or loss of expression, see for example Figure 3D and
Table 1). In our SCID mice experiments HYAL1 and HYAL2 genes
were inactivated (or tumours didn’t grow) even when the genes were
repressed (water with tetracycline). However we have already shown
that gene expression leakage in vivo is stronger than in vivo. Moreover
it is known that tetracycline is a weaker inhibitor of expression
compared to doxycycline in tTA system [9,14,15].
Thus, results clearly showed that the expression of either gene
has led to the inhibition of tumour growth in vivo, most likely by
influencing some interaction between the tumour cells and the
host, but without directly affecting tumour cell growth in vitro.
HYAL1 and HYAL2 thus differ in this aspect from other tumour
suppressors like P53 or RASSF1A that inhibit growth both in vitro
and in vivo. Since the products of both genes have a potential to
influence intercellular interactions, their impairment may inhibit
microenvironmental controls that normally protect the host from
tumour growth.
HYAL1 and HYAL2 are the major mammalian hyaluronidases in
somatic tissues. They may act in concert to degrade high molecular
weight hyaluronan (HA, a negatively charged, high molecular
weight glycosaminoglycan) to the tetrasaccharide level [23]. HYAL2
hydrolyses high molecular weight hyaluronic acid (or hyaluronate or
hyaluronan) to produce an intermediate-sized product which is
further hydrolysed by HYAL1 to give small oligosaccharides.
Hyaluronan is claimed to be involved in tumour invasion and
metastatic spread. The levels of HA surrounding tumour cells are
often correlated with tumour aggressiveness and poor outcome [24].
Overproduction of HA enhances anchorage-independent tu-
mour cell growth [25,26]. Loss of hyaluronidase activity,
Figure 3. Analysis of HYAL1 and HYAL2 stably transformed KRC/Y clones. Northern analysis (A) of tetracycline regulated clones. (+),
tetracycline (Tet) or doxycycline is present, gene is OFF. (2), tetracycline or doxycycline is absent, gene is ON. Growth inhibition of KRC/Y cells with
HYAL1 (B) and HYAL2 (C) transgenes in vitro. Tumour growth inhibition of KRC/Y cells by HYAL1 and HYAL2 in vivo in SCID mice (D). Mice were
drinking water with tetracycline (+Tet, gene is OFF) or without (2Tet, gene is ON) but for simplicity curves are shown only for mice when genes were
ON (no tetracycline).
doi:10.1371/journal.pone.0003031.g003
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permitting accumulation of HA, may be one of several steps
required by cells in the multi-step process of carcinogenesis [23].
In contrast to the tumour suppressor function of HYAL1 and
HYAL2 in these studies, no frequent inactivating mutations were
identified so far in these genes. Nevertheless it was reported that
HYAL1 was inactivated in six of seven head and neck squamous
cell carcinoma lines by illegitimate splicing [23,27]. We found that
the HYAL2 promoter was methylated in more than 50% of non-
small cell lung cancer (NSCLC) cases with decreased expression of
the HYAL2 (V. Senchenko, personal communication).
Suppressor activity of HYAL1 and HYAL2 was investigated in
the study of Ji et al. [28]. The results showed that HYAL1 and
HYAL2 did not significantly inhibit tumour cells growth neither in
vitro nor in vivo. However in this work it was demonstrated that
HYAL2 inhibited experimental lung metastases in nu/nu mice. It is
difficult to compare this work with our study. They used non-small
cell lung cancer cell lines and recombinant adenoviral vectors.
Completely different methods were used to measure suppressor
activity. Despite these differences main results are similar to our
work: HYAL1 and HYAL2 do not have strong growth inhibiting
activity in vitro and HYAL2 displayed some tumour suppressor
activity in vivo.
Since we demonstrated tumour suppressor function of HYAL1
and HYAL2 in SCID mice, we suggested that in primary renal and
lung cancers expression of these genes might also be distorted.
mRNA quantification was done for these genes in fifteen lung
(SCC) and fifteen kidney (RCC) tumours using qPCR. In the
majority of the tumour samples mRNA level of both genes was
significantly decreased (Figure 5), sometimes more than 50-fold.
The difference in expression level in tumour and normal tissues for
both SCC and RCC samples was statistically valid (P,0.02).
Interestingly, the expression of both genes frequently declined in
the same SCC samples. The correlation coefficient according to
Spearmen’s rank test between HYAL1 and HYAL2 mRNA level
was 0.67 (P= 0.005) in lung cancer samples (i.e statistically valid).
However in RCC samples it was only 0.4 (P= 0.14, i.e not
statistically valid). In any case, the results indicated that these genes
may play important role in the development of lung and renal
malignancies.
What genes could be responsible for the suppression of tumour
growth in vivo, without any inhibition of cell growth in vitro?
There are at least three conceivable categories: genes encoding
products required for responding to differentiation inducing
signals in vivo; products required for normal cellular responses to
microenvironmental controls; or genes whose products inhibit
angiogenesis [29].
Hyaluronidases are known to play an important role in tumour/
host interactions. They may be examples of genes encoding
interactive molecules that participate in microenvironmental
growth control and carcinogenesis.
There may be many other, as yet unidentified suppressor genes
with similarly asymmetric inhibitory properties. The large
Figure 4. CyQUANT Cell Proliferation Assay. Effect of expression of HYAL1 transgene in KRC/Y (A) and in U2020 (B) cells. The same is shown for
HYAL2 (KRC/Y in C and U2020 in D). Experiments were done in triplicates in the absence of doxycycline. The same experiments were done in the
presence of doxycycline and showed similar results (data not shown). Plotted data points represent averages of triplicate samples, the plotted line is a
linear regression fit of all data points. The assay is designed to produce a linear analytical response from at least 100–20,000 cells per well in most cell
lines.
doi:10.1371/journal.pone.0003031.g004
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numbers of LOHs that occur in the major human tumours and are
not accounted for by known tumour suppressor genes, as well as
the existence of ‘‘tumour suppressor gene clusters’’, as documented
on human chromosome 3p [11], point to a fertile area of further
investigation ahead.
Materials and Methods
Cell lines, tumour samples and general methods
Paired tumour/normal samples were obtained from Blokhin
Cancer Research Center, Russian Academy of Medical Sciences.
Altogether fifteen specimens of lung squamous cell carcinoma
(SCC) and fifteen clear cell renal carcinoma (RCC) cases and
adjacent morphologically normal tissues (conventional ‘‘normal’’
tissues) were obtained from patients after surgical resection of
primary tumours and and stored in liquid nitrogen.. Top and
bottom sections (3–5 mm thick) cut from frozen tumour tissues
were examined histologically and only samples containing 70% or
more tumour cells were used in the study. The samples were
collected in accordance to the guidelines issued by the Ethic
Committee of Blokhin Cancer Research Center, Russian Acad-
emy of Medical Sciences (Moscow). All patients gave written
informed consent that is available upon request. The study was
done in accordance with the principles outlined in the Declaration
of Helsinki. All tumor specimens were characterized according to
the International System of Clinico-Morphological Classification
of Tumors (TNM).
SCLC (small cell lung carcinoma) cell line U2020 was described
earlier [30] and RCC (renal cell carcinoma) cell line KRC/Y was
obtained from the MTC-KI (Stockholm, Sweden) cell lines
collection [1].
Molecular cloning of the human HYAL1, HYAL2 and FUS1
genes was described previously [6]. Spontaneous mutant FUS1mut
containing Val33Met amino acid substitution was isolated from
KRC/Y cell line transformed with wild type FUS1 (unpublished
data). These genes were re-cloned into the pETE vector [21].
Recombinants were confirmed by sequencing on ABI310
Sequencer (Applied Biosystems, Foster City, USA) according to
manufacturer’s protocol.
All molecular, cell biology and microbiology procedures were
performed as described previously [21,31].
Construction of U2020 and KRC/Y cell lines producing
tetracycline trans-activator tTA was described in [21].
Table 1. Growth of tumours in SCID mice.
Genes Clone Tetracycline Tumours PCR Northern
HYAL1 clone1 - T1 -
+ T2 -
- No tumour
+ No tumour
- T3 -
+ T4 -
clone4 - T5 -
+ T6 -
- T7 -
+ T8 -
HYAL2 clone13 - T9 -
+ T10 + NO EXPR
- No tumour
+ No tumour
- T11 -
+ T12 -
- No tumour
+ No tumour
clone14 - No tumour
+ No tumour
- No tumour
+ No tumour
doi:10.1371/journal.pone.0003031.t001
Figure 5. QPCR mRNA expression profile of HYAL1 and HYAL2 in SCC and RCC biopsies. The Y axis indicates the values of relative
expression level of target genes in log10 scale in tumour samples relative to control normal samples normalized to the reference gene GAPDH. The X
axis shows the cDNA samples isolated from tumours at different stages (I–III). Open bars show HYAL1 and hatched bars HYAL2 expression.
doi:10.1371/journal.pone.0003031.g005
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Transfection, positive clone selection and Northern
blotting
Plasmid DNAs containing HYAL1, HYAL2, FUS1 and FUS1mut
genes were purified using R.E.A.L. Prep kit (Qiagen, Valencia,
CA). Transfections were performed using Lipofectamine PLUS
Reagent (Life Technologies, Rockville, MD) according to the
manufacturer’s protocol.
After transfection, cells were selected with 200U/ml Hygro-
mycin and 200ng/ml doxycycline for four weeks.
PCR positive clones from each recombinant were grown in
Iscove’s cell culture medium supplemented with 10% heat-
inactivated FBS, 100 mg/ml penicillin, 100 mg/ml streptomycin,
200 U/ml hygromycin and 200ng/ml doxycycline. Each clone
was split into two parallel flasks, in one of them cells were grown
without doxycycline. After one week, 106 cells were collected and
total RNA was isolated with TrizolH reagent (Life Technologies,
Rockville, MD).
Northern blotting and hybridization were performed as
described before [9,14,15]. HYAL1 and HYAL2 probes were
purified using electrophoresis and the Jetquick Gel Purification kit
(Saveen, Germany). The probes were labeled with a-P32 dCTP by
random labeling.
All growth inhibition experiments in vivo and in vitro were done
as described previously [9,13,14,21]. Work with SCID mice has
been approved by North Stockholm Ethical Committee, decision
No. 150/08.
Briefly, U2020 or KRC/Y cells were transfected with plasmid
DNA using Lipofectamine/Plus reagent (Invitrogen, Germany).
Transfected cells were stripped and plated on 100 mm cell culture
plates. After selection with 400 mg/ml Hygromycin for 2 weeks,
Giemsa-stained colonies were photographed and counted.
The tumorigenicity of each cell line was tested by subcutaneous
injection. In total, 56106 cells were injected into 4-week old female
SCID mice. Each mouse received only 1 injection. Twelve control
mice were injected with empty pETE vector (six mice were
drinking water with DOX and six without). Twenty two mice were
used for the experiments (see Table 1). Tumour growth in animals
was checked twice a week, if tumour formation was observed,
tumours were measured using calipers.
Cell proliferation assay
Cell proliferation rate was determined using CyQUANT NF
Cell Proliferation Assay (Invitrogen) according to the manufac-
turer’s protocol. Briefly, cells were plated at density of 100–500
cells per well in a 96-well plate (totally 8–12 identical wells).
Number of cells in wells was counted every 24 hours: growth
medium was removed, 50 ml of green-fluorescent CyQUANT GR
dye (which exhibits strong fluorescence enhancement when bound
to cellular nucleic acid) was added to the well and incubated for
30 min at 37uC. The fluorescence intensity of each sample was
measured using a fluorescence microplate reader with excitation at
485nm and emission detection at 530nm. Plotted data points
represent averages of triplicate samples, the plotted line is a linear
regression fit of all data points. The assay is designed to produce a
linear analytical response from at least 100–20,000 cells per well in
most cell lines.
Quantitative real-time PCR (qPCR)
RNA isolated from primary tumour samples was reverse
transcribed using the GeneAmpH RNA PCR Kit (Applied
Biosystems) according to the manufacturer’s protocol. The relative
mRNA level of target genes and GAPDH was assessed using qPCR
(ABI PRISM H 7000 Sequence Detection System, Applied
Biosystems). Ratio of mRNA level of target genes in all analysed
tumours was measured relative to the reference ‘‘normal’’ samples
(paired morphologically normal tissues obtained from the same
patient).
The primers and probes for transcripts were as follows:
HYAL1:
Forward primer, 59- TTTCTGCCCCTGGATGAGC-39;
Reverse primer, 59-CTCACCCAGAGCACCACTCC-39;
Probe, 59-FAM-CCCAGGCTGTGCTCCAGCTCA-[RTQ1]-
39;
(amplicon size 80 bp);
HYAL2:
Forward primer, 59- CACCACAAGCACGGAGACCT-39;
Reverse primer, 59-CAGGCACTAGGCGGAAACTG-39;
Probe 59-FAM-CCTTCCTGCATCTCAGCACCAACAG-
[RTQ1]-39;
(amplicon size 197 bp);
GAPDH:
Forward primer, 59- CGGAGTCAACGGATTTGGTC– 39;
Reverse primer, 59- TGGGTGGAATCATATTGGAACAT– 39;
Probe, 59-FAM-CCCTTCATTGACCTCAACTACATGGT-
TTACAT–[RTQ1]-39;
(amplicon size 141 bp);
The optimal primer and probe concentrations for the target and
control genes were as follows:
HYAL1 primers, 300 nM, probe, 300 nM (for lung cancer
cDNA samples); primers, 200 nM, probe, 200 nM (for RCC
cDNA samples);
HYAL2 primers, 300 nM, probe, 300 nM (for lung cancer
cDNA samples); primers, 200 nM, probe, 200 nM (for RCC
cDNA samples);
GAPDH primers, 300 nM; probe, 150 nM.
The thermocycler conditions were 10 min at 95uC, then 50
two-step cycles 15sec at 95uC and 60sec at 60u C. qPCR
amplification was carried out in triplicate in 25-ml reaction volume
using TaqMan Universal Master Mix (Applied Biosystems) and
10ng template cDNA. The sequences of the amplicons were
verified by sequencing in 3730 DNA Analyzer automated
sequencer (Applied Biosystems).
The comparative CT method was used as described previously
[4,5].
Statistical analysis
Nonparametric Wilcoxon test was used to compare mRNA
expression differences of HYAL1 and HYAL2 and reference gene
for the same SCC and RCC patients. The evaluation of statistical
significance of mRNA level was tested for all studied cases.
Nonparametric Spearmen’s rank test was used to calculate the
coefficient of correlation between the level of mRNA decrease for
HYAL1 and HYAL2 genes. P-values ,0.05 were considered
statistically significant. All statistical procedures were performed
using BioStat software [32].
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